



Market Announcement

10 October 2019

Cellmid Limited (ASX: CDY) – Trading Halt

Description

The securities of Cellmid Limited ('CDY') will be placed in trading halt at the request of CDY, pending it releasing an announcement regarding a proposed capital raising. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 14 October 2019 or when the announcement is released to the market.

Issued by

Maria Clemente

Adviser, Listings Compliance (Sydney)

10 October 2019

Lisa Banh
Senior Adviser, Listings Compliance
Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

By Email: tradinghaltssydney@asx.com.au

Dear Lisa,

ASX Code: CDY – Trading Halt Request

Pursuant to ASX Listing Rule 17.1, Cellmid Limited (ASX:CDY) (**Company**) requests a trading halt of its securities effective immediately.

The trading halt is requested pending the release of an ASX announcement regarding a proposed capital raising.

It is expected the trading halt will end on the earlier of the commencement of normal trading on Monday, 14 October 2019, or when an announcement on the proposed capital raising is released to the market.

The Company is not aware of any reason why the trading halt should not be granted.

Yours faithfully

Lee Tamplin
Company Secretary

End

Contact:

Maria Halasz, CEO
T +612 9221 6830



@mariahalasz

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with a consumer health business and biotech assets. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au .

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.